Youli Zu

Houston Methodist

*This is an algorithmically generated author record based on publicly available information.

See Latest Publications

See Most Cited Publications

SciProfiles

ORCID Profile

Google Scholar

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Houston Methodist

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years

Research Subjects

Research Interests

Youli Zu has a total of 274 co-authors. Here are the top co-authors by number of shared publications:

Zihua Zeng
Department of Pathology and Genomic Medicine, Houston Methodist Hospital, USA
18 shared publications
Alan Hodges
Center for Immunotherapy, Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas
11 shared publications
Brooke Prinzing
Department of Bone Marrow Transplantation & Cellular Therapy, St Jude Children's Research Hospital, Memphis, Tennessee
11 shared publications
Fumiko Nakatsu
Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York
11 shared publications
Hui-Ming Chen
Center for Immunotherapy, Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas
11 shared publications
Jilu Zhang
Center for Immunotherapy, Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas
11 shared publications

Latest Publications

Sort by

Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1. LILRB1-4 surface expression in AML patient samples from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
by Sunny Mai, Alan Hodges, Hui-Ming Chen, Jilu Zhang, Yi-Ling Wang, Yongbin Liu, Fumiko Nakatsu, Xiaoxuan Wang, Jing Fang, Yitian Xu, et al.
Percent LILRB1-4 positive cells in human AML PBMC. Gated on viable CD33+ cells
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Table S1. LILRB1-4 surface expression in AML patient samples from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
by Sunny Mai, Alan Hodges, Hui-Ming Chen, Jilu Zhang, Yi-Ling Wang, Yongbin Liu, Fumiko Nakatsu, Xiaoxuan Wang, Jing Fang, Yitian Xu, et al.
Percent LILRB1-4 positive cells in human AML PBMC. Gated on viable CD33+ cells
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
by Sunny Mai, Alan Hodges, Hui-Ming Chen, Jilu Zhang, Yi-Ling Wang, Yongbin Liu, Fumiko Nakatsu, Xiaoxuan Wang, Jing Fang, Yitian Xu, et al.
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Data from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
by Sunny Mai, Alan Hodges, Hui-Ming Chen, Jilu Zhang, Yi-Ling Wang, Yongbin Liu, Fumiko Nakatsu, Xiaoxuan Wang, Jing Fang, Yitian Xu, et al.
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2. Ingenuity Pathway Analysis of LILRB3 antibody treated U937 cells from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
by Sunny Mai, Alan Hodges, Hui-Ming Chen, Jilu Zhang, Yi-Ling Wang, Yongbin Liu, Fumiko Nakatsu, Xiaoxuan Wang, Jing Fang, Yitian Xu, et al.
Pathway analysis of LILRB3 antibody treated U937 cells.
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Table S2. Ingenuity Pathway Analysis of LILRB3 antibody treated U937 cells from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
by Sunny Mai, Alan Hodges, Hui-Ming Chen, Jilu Zhang, Yi-Ling Wang, Yongbin Liu, Fumiko Nakatsu, Xiaoxuan Wang, Jing Fang, Yitian Xu, et al.
Pathway analysis of LILRB3 antibody treated U937 cells.
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3. CBC+CMP from LILRB3 CAR T adoptively transferred LILRB3 transgenic mice from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
by Sunny Mai, Alan Hodges, Hui-Ming Chen, Jilu Zhang, Yi-Ling Wang, Yongbin Liu, Fumiko Nakatsu, Xiaoxuan Wang, Jing Fang, Yitian Xu, et al.
Complete Blood Counts and Metabolic Panel for LILRB3 specific CAR adoptively transferred LILRB3 transgenic naive mice.
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Table S3. CBC+CMP from LILRB3 CAR T adoptively transferred LILRB3 transgenic mice from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
by Sunny Mai, Alan Hodges, Hui-Ming Chen, Jilu Zhang, Yi-Ling Wang, Yongbin Liu, Fumiko Nakatsu, Xiaoxuan Wang, Jing Fang, Yitian Xu, et al.
Complete Blood Counts and Metabolic Panel for LILRB3 specific CAR adoptively transferred LILRB3 transgenic naive mice.
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
by Sunny Mai, Alan Hodges, Hui-Ming Chen, Jilu Zhang, Yi-Ling Wang, Yongbin Liu, Fumiko Nakatsu, Xiaoxuan Wang, Jing Fang, Yitian Xu, et al.
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figures from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
by Sunny Mai, Alan Hodges, Hui-Ming Chen, Jilu Zhang, Yi-Ling Wang, Yongbin Liu, Fumiko Nakatsu, Xiaoxuan Wang, Jing Fang, Yitian Xu, et al.
Open Access
Website
Google Scholar
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Table S2. Ingenuity Pathway Analysis of LILRB3 antibody treated U937 cells from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
by Sunny Mai, Alan Hodges, Hui-Ming Chen, Jilu Zhang, Yi-Ling Wang, Yongbin Liu, Fumiko Nakatsu, Xiaoxuan Wang, Jing Fang, Yitian Xu, et al.
Pathway analysis of LILRB3 antibody treated U937 cells.
Website
Google Scholar
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Table S2. Ingenuity Pathway Analysis of LILRB3 antibody treated U937 cells from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
by Sunny Mai, Alan Hodges, Hui-Ming Chen, Jilu Zhang, Yi-Ling Wang, Yongbin Liu, Fumiko Nakatsu, Xiaoxuan Wang, Jing Fang, Yitian Xu, et al.
Pathway analysis of LILRB3 antibody treated U937 cells.
Open Access
Website
Google Scholar
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Table S1. LILRB1-4 surface expression in AML patient samples from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
by Sunny Mai, Alan Hodges, Hui-Ming Chen, Jilu Zhang, Yi-Ling Wang, Yongbin Liu, Fumiko Nakatsu, Xiaoxuan Wang, Jing Fang, Yitian Xu, et al.
Percent LILRB1-4 positive cells in human AML PBMC. Gated on viable CD33+ cells
Website
Google Scholar
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Table S1. LILRB1-4 surface expression in AML patient samples from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
by Sunny Mai, Alan Hodges, Hui-Ming Chen, Jilu Zhang, Yi-Ling Wang, Yongbin Liu, Fumiko Nakatsu, Xiaoxuan Wang, Jing Fang, Yitian Xu, et al.
Percent LILRB1-4 positive cells in human AML PBMC. Gated on viable CD33+ cells
Open Access
Website
Google Scholar
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
by Sunny Mai, Alan Hodges, Hui-Ming Chen, Jilu Zhang, Yi-Ling Wang, Yongbin Liu, Fumiko Nakatsu, Xiaoxuan Wang, Jing Fang, Yitian Xu, et al.
Website
Google Scholar
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Data from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
by Sunny Mai, Alan Hodges, Hui-Ming Chen, Jilu Zhang, Yi-Ling Wang, Yongbin Liu, Fumiko Nakatsu, Xiaoxuan Wang, Jing Fang, Yitian Xu, et al.
Open Access
Website
Google Scholar
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
by Sunny Mai, Alan Hodges, Hui-Ming Chen, Jilu Zhang, Yi-Ling Wang, Yongbin Liu, Fumiko Nakatsu, Xiaoxuan Wang, Jing Fang, Yitian Xu, et al.
Website
Google Scholar
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figures from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
by Sunny Mai, Alan Hodges, Hui-Ming Chen, Jilu Zhang, Yi-Ling Wang, Yongbin Liu, Fumiko Nakatsu, Xiaoxuan Wang, Jing Fang, Yitian Xu, et al.
Open Access
Website
Google Scholar
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Table S3. CBC+CMP from LILRB3 CAR T adoptively transferred LILRB3 transgenic mice from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
by Sunny Mai, Alan Hodges, Hui-Ming Chen, Jilu Zhang, Yi-Ling Wang, Yongbin Liu, Fumiko Nakatsu, Xiaoxuan Wang, Jing Fang, Yitian Xu, et al.
Complete Blood Counts and Metabolic Panel for LILRB3 specific CAR adoptively transferred LILRB3 transgenic naive mice.
Website
Google Scholar
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Table S3. CBC+CMP from LILRB3 CAR T adoptively transferred LILRB3 transgenic mice from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
by Sunny Mai, Alan Hodges, Hui-Ming Chen, Jilu Zhang, Yi-Ling Wang, Yongbin Liu, Fumiko Nakatsu, Xiaoxuan Wang, Jing Fang, Yitian Xu, et al.
Complete Blood Counts and Metabolic Panel for LILRB3 specific CAR adoptively transferred LILRB3 transgenic naive mice.

Show all